Search Results - "Mabry, Mack"

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer by RUDIN, Charles M, HANN, Christine L, RANSON, Malcolm R, DIVE, Caroline, MCKEEGAN, Evelyn M, CHYLA, Brenda J, DOWELL, Barry L, CHAKRAVARTTY, Arunava, NOLAN, Cathy E, RUDERSDORF, Niki, BUSMAN, Todd A, MABRY, Mack H, GARON, Edward B, KRIVOSHIK, Andrew P, HUMERICKHOUSE, Rod A, SHAPIRO, Geoffrey I, GANDHI, Leena, DE OLIVEIRA, Moacyr Ribeiro, BONOMI, Philip D, ROSS CAMIDGE, D, CHU, Quincy, GIACCONE, Giuseppe, KHAIRA, Divis, RAMALINGAM, Suresh S

“…Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of small cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and…”
Get full text

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study by DiNardo, Courtney D, Pratz, Keith W, Letai, Anthony, Jonas, Brian A, Wei, Andrew H, Thirman, Michael, Arellano, Martha, Frattini, Mark G, Kantarjian, Hagop, Popovic, Relja, Chyla, Brenda, Xu, Tu, Dunbar, Martin, Agarwal, Suresh K, Humerickhouse, Rod, Mabry, Mack, Potluri, Jalaja, Konopleva, Marina, Pollyea, Daniel A

“…Elderly patients (aged ≥65 years) with acute myeloid leukaemia have poor outcomes and no effective standard-of-care therapy exists. Treatment with…”
Get full text

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia by Konopleva, Marina, Pollyea, Daniel A, Potluri, Jalaja, Chyla, Brenda, Hogdal, Leah, Busman, Todd, McKeegan, Evelyn, Salem, Ahmed Hamed, Zhu, Ming, Ricker, Justin L, Blum, William, DiNardo, Courtney D, Kadia, Tapan, Dunbar, Martin, Kirby, Rachel, Falotico, Nancy, Leverson, Joel, Humerickhouse, Rod, Mabry, Mack, Stone, Richard, Kantarjian, Hagop, Letai, Anthony

“…We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor…”
Get more information

An achaete-scute homologue essential for neuroendocrine differentiation in the lung by Borges, Michael, Linnoila, R. Ilona, van de Velde, Helgi J. K, Chen, Herbert, Nelkin, Barry D, Mabry, Mack, Baylin, Stephen B, Ball, Douglas W

Get full text

Phase 3, randomized, double-blind, placebo-controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naïve patients with acute myeloid leukemia by Potluri, Jalaja, Xu, Tu, Hong, Wan-Jen, Mabry, Mack H.

“…Abstract only TPS7069 Background: Elderly acute myeloid leukemia (AML) is a biologically and clinically distinct disease with a diminished response to…”
Get full text

Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia by Chyla, Brenda, Popovic, Relja, Potluri, Jalaja, Hayslip, John, Huang, Xin, Zhu, Ming, Mabry, Mack, Bhathena, Anahita

“…Background: We recently reported encouraging antileukemic activity of venetoclax, an orally available selective BCL-2 inhibitor, in combination with…”
Get full text

A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors by Vlahovic, Gordana, Karantza, Vassiliki, Wang, Ding, Cosgrove, David, Rudersdorf, Nikita, Yang, Jianning, Xiong, Hao, Busman, Todd, Mabry, Mack

“…Summary Bcl-2 family proteins are the key regulators of the intrinsic apoptotic pathway, controlling the point-of no-return and setting the threshold to engage…”
Get full text

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors by Cleary, James M., Lima, Caio Max S. Rocha, Hurwitz, Herbert I., Montero, Alberto J., Franklin, Catherine, Yang, Jianning, Graham, Alison, Busman, Todd, Mabry, Mack, Holen, Kyle, Shapiro, Geoffrey I., Uronis, Hope

“…Summary Purpose : To investigate the safety, optimal dosing, pharmacokinetics and clinical activity of a regimen of navitoclax (ABT-263) combined with…”
Get full text

Updated Safety and Efficacy of Venetoclax with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia by DiNardo, Courtney D., Pollyea, Daniel A., Jonas, Brian A, Konopleva, Marina, Pullarkat, Vinod, Wei, Andrew, Kantarjian, Hagop M., Pigneux, Arnaud, Recher, Christian, Seymour, John F, Dunbar, Martin, Xu, Tu, Mabry, Mack, Potluri, Jalaja, Pratz, Keith, Letai, Anthony

“…▪ Background: Venetoclax (VEN) is an oral, small molecule inhibitor of the anti-apoptotic protein BCL-2, which may mediate the viability and chemoresistance of…”
Get full text

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes by Wei, Andrew, Strickland, Stephen A., Roboz, Gail J., Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L., Walter, Roland B., Enjeti, Anoop, Chyla, Brenda, Popovic, Relja, Fakouhi, Kaffa, Shah, Pooja, Dunbar, Martin, Xu, Tu, Mabry, Mack, Hayslip, John

“…Background: Older patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy are unlikely to achieve remission with available…”
Get full text

Abstract CT069: Correlative biomarkers of clinical activity of the BCL-2 inhibitor, venetoclax (ABT-199/ GDC-0199), in acute myeloid leukemia patients by Popovic, Relja, Daver, Naval, Ruvolo, Vivian, Chen, Ken, Wang, Zixing, Huang, Xin, Mabry, Mack, Potluri, Jalaja, McKeegan, Evelyn, Konopleva, Marina, Chyla, Brenda J.

“…Abstract A phase 2 trial evaluated the efficacy and safety of venetoclax monotherapy in 32 patients (pts) with relapsed/refractory acute myeloid leukemia (AML)…”
Get full text

Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes by Fong, Chun Yew, Wei, Andrew H., Frattini, Mark G., Jacoby, Meagan, Borate, Uma, Gotze, Katharina S., Garcia, Jacqueline Suen, Pollyea, Daniel Aaron, Holes, Leanne, Zhou, Ying, Fakouhi, Kaffa Mussumeh, Leverson, Joel, Harb, Jason G, Agarwal, Suresh K., Attarchi, Faraneh, Mabry, Mack H., Hong, Wan-Jen, Jahn, Thomas Michael, Fenaux, Pierre, Garcia-Manero, Guillermo

“…Abstract only…”
Get full text

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia by Wei, Andrew, Strickland, Stephen A., Roboz, Gail J., Hou, Jing-Zhou, Fiedler, Walter, Lin, Tara L., Martinelli, Giovanni, Walter, Roland B., Enjeti, Anoop, Fakouhi, Kaffa, Darden, David E., Dunbar, Martin, Zhu, Ming, Agarwal, Suresh, Salem, Ahmed H., Mabry, Mack, Hayslip, John

“…▪ Background: Multiple studies have demonstrated the modest efficacy of low-dose cytarabine (LDAC) in older patients (≥65 years) with Acute Myeloid…”
Get full text

Abstract B10: Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia by Hogdal, Leah, Chyla, Brenda, McKeegan, Evelyn, Leverson, Joel, Potluri, Jalaja, Humerickhouse, Rod, Mack, Mabry, DeAngelo, Daniel, Galinsky, Ilene, Stone, Richard, Letai, Anthony

“…Abstract Most patients with acute myeloid leukemia (AML) become resistant to chemotherapy at some point in their course and succumb to their disease. It is…”
Get full text

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy by DiNardo, Courtney, Pollyea, Daniel, Pratz, Keith, Thirman, Michael J., Letai, Anthony, Frattini, Mark, Jonas, Brian, Leverson, Joel, Zhu, Ming, Dunbar, Martin, Falotico, Nancy, Kirby, Rachel, Agarwal, Suresh, Mabry, Mack, Potluri, Jalaja, Humerickhouse, Rod A., Kantarjian, Hagop M., Konopleva, Marina

“…▪ Introduction: Overexpression of the antiapoptotic protein BCL-2 has been implicated in the maintenance and survival of acute myelogenous leukemia (AML) cells…”
Get full text

Abstract 2834: BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia by Hogdal, Leah, Chyla, Brenda, McKeegan, Evelyn, Leverson, Joel, Potluri, Jalaja, Falotico, Nancy, Ricker, Justin, Humerickhouse, Rod, Mabry, Mack, Foight, Glenna, Keating, Amy, Galinsky, Ilene, Stone, Richard, DeAngelo, Daniel, Konopleva, Marina, Letai, Anthony

“…Abstract Background: ABT-199 is a potent and selective small molecule inhibitor of the anti-apoptotic protein BCL-2, currently in a Phase II clinical trial for…”
Get full text

Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy by Pollyea, Daniel Aaron, Dinardo, Courtney Denton, Thirman, Michael J., Letai, Anthony, Wei, Andrew H., Jonas, Brian Andrew, Arellano, Martha Lucia, Frattini, Mark G, Kantarjian, Hagop M, Chyla, Brenda, Zhu, Ming, Potluri, Jalaja, Humerickhouse, Rod, Mabry, Mack H., Konopleva, Marina, Pratz, Keith William

“…Abstract only…”
Get full text

A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) by Konopleva, Marina, Pollyea, Daniel A., Potluri, Jalaja, Chyla, Brenda J., Busman, Todd, McKeegan, Evelyn, Salem, Ahmed, Zhu, Ming, Ricker, Justin L., Blum, William, DiNardo, Courtney D., Dunbar, Martin, Kirby, Rachel, Falotico, Nancy, Leverson, Joel D., Humerickhouse, Rod A., Mabry, Mack, Stone, Richard M., Kantarjian, Hagop M., Letai, Anthony G.

“…Introduction: BCL-2 has been implicated in hematologic malignancies and associated with drug resistance and poor prognosis in acute myelogenous leukemia (AML)…”
Get full text

Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase by Yao, S L, Akhtar, A J, McKenna, K A, Bedi, G C, Sidransky, D, Mabry, M, Ravi, R, Collector, M I, Jones, R J, Sharkis, S J, Fuchs, E J, Bedi, A

“…The induction of tumor cell death by anticancer therapy results from a genetic program of autonomous cell death termed apoptosis. Because the p53 tumor…”
Get full text

An achaete-scute homologue essential for neuroendocrine differentiation in the lung by Borges, M, Linnoila, R I, van de Velde, H J, Chen, H, Nelkin, B D, Mabry, M, Baylin, S B, Ball, D W

“…In Drosophila and in vertebrates, the achaete-scute family of basic helix-loop-helix transcription factors plays a critical developmental role in neuronal…”
Get full text